<![CDATA[Reviewing the HIMALAYA Trial of Tremelimumab Plus Durvalumab in Unresectable HCC]]>
Trending
- 40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study
- 39 Predictors of Delay in Time From Diagnostic Breast Imaging to Needle Core Biopsy
- Postoperative dynamics of inflammatory markers in patients with uncomplicated recovery after colorectal cancer surgery: a preliminary inflammatory benchmarks study
- Kate completes Three Peaks challenge to raise money for cancer charity | Catherine, Princess of Wales
- Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines
- What adolescents and young adults with cancer want researchers to know
- Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use
- New vitamin B12 therapy shows promise against deadly brain cancer

![<![CDATA[Reviewing the HIMALAYA Trial of Tremelimumab Plus Durvalumab in Unresectable HCC]]> Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG-3 can reverse checkpoint inhibitor resistance.](https://news.shareyourcancerstories.com/wp-content/uploads/2026/06/ltCDATAReviewing-the-HIMALAYA-Trial-of-Tremelimumab-Plus-Durvalumab-in-Unresectable-768x432.png)